Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

ABACUS. Repositorio de Producción Científica
Publication Artículo científico (JournalArticle)

Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study

  • Díaz Muñoz, Raquel
  • Valle Caballero, María José
  • Sánchez González, Javier
  • Pizarro, Gonzalo
  • García Rubira, Juan Carlos
  • Escalera, Noemí
  • Fuster, Valentín
  • Fernández Jiménez, Rodrigo
  • Ibáñez Cabeza, Borja
Besides its protective effect against neutrophil-mediated injury at reperfusion, intravenous (IV) metoprolol was recently shown to reduce the progression of ischemic injury in a pig model of ST-segment elevation myocardial infarction (STEMI). Here, we tested the hypothesis that IV metoprolol administration in humans with ongoing STEMI blunts the time‑dependent progression of ischemic injury assessed by serial electrocardiogram (ECG) evaluations before reperfusion. The METOCARD-CNIC trial randomized 270 anterior STEMI patients to IV metoprolol or control before reperfusion by percutaneous coronary intervention (PCI). In 139 patients (69 IV metoprolol, 70 controls), two ECGs were available (ECG-1 before randomization, ECG-2 pre-PCI). Between-group ECG differences were analyzed using univariate and multivariate regression models. No significant between-group differences were observed on ECG-1. On ECG-2, patients who received IV metoprolol had a narrower QRS than those in the control group (84 ms vs. 90 ms, p = 0.029), a lower prevalence of QRS distortion (10% vs. 26%, p = 0.017), and a lower sum of anterior and total ST-segment elevation (10.1 mm vs. 13.6 mm, p = 0.014 and 10.4 mm vs. 14.0 mm, p = 0.015, respectively). Adjusted analysis revealed similar results. Significant associations were observed between ECG-2 variables and cardiac magnetic resonance imaging measurements (extent of myocardial edema, infarct size, microvascular obstruction, and left-ventricular ejection fraction) after STEMI. In summary, IV metoprolol administration before reperfusion ameliorates ECG markers of myocardial ischemia in anterior STEMI patients. These data confirm that IV metoprolol is able to reduce ischemic injury and highlight the ability of ECG analysis to provide relevant real-time information on the effect of cardioprotective therapies before reperfusion.
Repisalud
Publication Artículo científico (JournalArticle)

Influence of Subclinical Atherosclerosis Burden and Progression on Mortality.

  • Fuster, Valentin
  • García-Álvarez, Ana
  • Devesa, Ana
  • Mass, Virginia
  • Owen, Ruth
  • Quesada, Antonio
  • Fuster, José J
  • García-Lunar, Inés
  • Pocock, Stuart
  • Sánchez-González, Javier
  • Sartori, Samantha
  • Peyra, Carlos
  • Andres, Vicente
  • Muntendam, Pieter
  • Ibanez, Borja
Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality. A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable. Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P < 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm change; P = 0.01). Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.
Repisalud
Publication Artículo científico (JournalArticle)

Coronary Microvascular Function in Asymptomatic Middle-Aged Individuals With Cardiometabolic Risk Factors.

  • Devesa, Ana
  • Fuster, Valentin
  • García-Lunar, Inés
  • Oliva, Belén
  • García-Alvarez, Ana
  • Moreno-Arciniegas, Andrea
  • Vazirani, Ravi
  • Pérez-Herreras, Cristina
  • Marina, Pablo
  • Bueno, Héctor
  • Fernández-Friera, Leticia
  • Fernández-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Devesa, Ana
  • Fuster, Valentin
  • García-Lunar, Inés
  • Oliva, Belén
  • García-Alvarez, Ana
  • Moreno-Arciniegas, Andrea
  • Vazirani, Ravi
  • Pérez-Herreras, Cristina
  • Marina, Pablo
  • Bueno, Héctor
  • Fernández-Friera, Leticia
  • Fernández-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
In patients with ischemic heart disease, coronary microvascular dysfunction is associated with cardiovascular risk factors and poor prognosis; however, data from healthy individuals are scarce. The purpose of this study was to assess the impact of cardiovascular risk factors and subclinical atherosclerosis on coronary microvascular function in middle-aged asymptomatic individuals. Myocardial perfusion was measured at rest and under stress using cardiac magnetic resonance in 453 individuals and used to generate myocardial blood flow (MBF) maps and calculate myocardial perfusion reserve (MPR). Subclinical atherosclerosis was assessed using 3-dimensional vascular ultrasound of the carotid and femoral arteries and coronary artery calcium scoring at baseline and at 3-year follow-up. Median participant age was 52.6 years (range: 48.9-55.8 years), and 84.5% were male. After adjusting for age and sex, rest MBF was directly associated with the number of the metabolic syndrome components present (elevated waist circumference, systolic and diastolic blood pressure, fasting glucose, and triglycerides and low high-density lipoprotein cholesterol), insulin resistance (homeostatic model assessment for insulin resistance), and presence of diabetes. MPR was reduced in the presence of several metabolic syndrome components, elevated homeostatic model assessment for insulin resistance, and diabetes. Stress MBF was inversely associated with coronary artery calcium presence and with global plaque burden. Higher stress MBF and MPR were associated with less atherosclerosis progression (increase in plaque volume) at 3 years. In asymptomatic middle-aged individuals free of known cardiovascular disease, the presence of cardiometabolic risk factors and systemic (poly-vascular) subclinical atherosclerosis are associated with impaired coronary microvascular function. Better coronary microvascular function reduces atherosclerosis progression at follow-up. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).
Repisalud
Publication Artículo científico (JournalArticle)

Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control: Novel Therapeutic Target.

  • Díaz-Guerra, Anabel
  • Villena-Gutierrez, Rocio
  • Clemente-Moragón, Agustín
  • Gomez, Monica
  • Oliver, Eduardo
  • Fernández-Tocino, Miguel
  • Galan-Arriola, Carlos
  • Cádiz, Laura
  • Ibáñez, Borja
BACKGROUND Anthracycline-induced cardiotoxicity (AIC) debilitates quality of life in cancer survivors. Serial characterizations are lacking of the molecular processes occurring with AIC. OBJECTIVES The aim of this study was to characterize AIC progression in a mouse model from early (subclinical) to advanced heart failure stages, with an emphasis on cardiac metabolism and mitochondrial structure and function. METHODS CD1 mice received 5 weekly intraperitoneal doxorubicin injections (5 mg/kg) and were followed by serial echocardiography for 15 weeks. At 1, 9, and 15 weeks after the doxorubicin injections, mice underwent fluorodeoxyglucose positron emission tomography, and hearts were extracted for microscopy and molecular analysis. RESULTS Cardiac atrophy was evident at 1 week post-doxorubicin (left ventricular [LV] mass 117 ± 26 mg vs 97 ± 25 mg at baseline and 1 week, respectively; P < 0.001). Cardiac mass nadir was observed at week 3 post-doxorubicin (79 ± 16 mg; P = 0.002 vs baseline), remaining unchanged thereafter. Histology confirmed significantly reduced cardiomyocyte area (167 ± 19 μm2 in doxorubicin-treated mice vs 211 ± 26 μm2 in controls; P = 0.004). LV ejection fraction declined from week 6 post-doxorubicin (49% ± 9% vs 61% ± 9% at baseline; P < 0.001) until the end of follow-up at 15 weeks (43% ± 8%; P < 0.001 vs baseline). At 1 week post-doxorubicin, when LV ejection fraction remained normal, reduced cardiac metabolism was evident from down-regulated markers of fatty acid oxidation and glycolysis. Metabolic impairment continued to the end of follow-up in parallel with reduced mitochondrial adenosine triphosphate production. A transient early up-regulation of nutrient-sensing and mitophagy markers were observed, which was associated with mitochondrial enlargement. Later stages, when mitophagy was exhausted, were characterized by overt mitochondrial fragmentation. CONCLUSIONS Cardiac atrophy, global hypometabolism, early transient-enhanced mitophagy, biogenesis, and nutrient sensing constitute candidate targets for AIC prevention.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Unidirectional association of clonal hematopoiesis with atherosclerosis development.

  • Díez-Díez, Miriam
  • Ramos-Neble, Beatriz L
  • de la Barrera, Jorge
  • Silla-Castro, J C
  • Quintas, Ana
  • Vázquez, Enrique
  • Rey-Martín, M Ascensión
  • Izzi, Benedetta
  • Sánchez-García, Lucía
  • García-Lunar, Inés
  • Mendieta, Guiomar
  • Mass, Virginia
  • Gómez-López, Nuria
  • Espadas, Cristina
  • González, Gema
  • Quesada, Antonio J
  • García-Álvarez, Ana
  • Fernández-Ortiz, Antonio
  • Lara-Pezzi, Enrique
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Ibáñez, Borja
  • Andrés, Vicente
  • Fuster, Valentín
  • Fuster, José J
Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological cancer and a growing list of nonhematological disorders, most notably atherosclerosis and associated cardiovascular disease. However, whether accelerated atherosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate. Some studies support a direct contribution of certain clonal hematopoiesis-related mutations to atherosclerosis via exacerbation of inflammatory responses, whereas others suggest that clonal hematopoiesis is a symptom rather than a cause of atherosclerosis, as atherosclerosis or related traits may accelerate the expansion of mutant hematopoietic clones. Here we combine high-sensitivity DNA sequencing in blood and noninvasive vascular imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudinal cohort of healthy middle-aged individuals. We found that the presence of a clonal hematopoiesis-related mutation confers an increased risk of developing de novo femoral atherosclerosis over a 6-year period, whereas neither the presence nor the extent of atherosclerosis affects mutant cell expansion during this timeframe. These findings indicate that clonal hematopoiesis unidirectionally promotes atherosclerosis, which should help translate the growing understanding of this condition into strategies for the prevention of atherosclerotic cardiovascular disease in individuals exhibiting clonal hematopoiesis.
Repisalud
Publication Artículo científico (JournalArticle)

Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

  • Rossello, Xavier
  • Raposeiras-Roubin, Sergio
  • Oliva, Belén
  • Sanchez-Cabo, Fatima
  • García-Ruíz, José M
  • Caimari, Francisca
  • Mendiguren, José M
  • Lara-Pezzi, Enrique
  • Bueno, Hector
  • Fernández-Friera, Leticia
  • Fernández-Ortiz, Antonio
  • Sanz, Javier
  • Ibáñez, Borja
  • Fuster, Valentin
Background: The metabolic injury caused by protein glycation, monitored as the level of glycated hemoglobin (HbA1c), is not represented in most risk scores (i.e., Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease risk scale). Objectives: The purpose of this study was to assess the association between HbA1c and the extent of subclinical atherosclerosis (SA) and to better identify individuals at higher risk of extensive SA using HbA1c on top of key cardiovascular risk factors (CVRFs). Methods: A cohort of 3,973 middle-aged individuals from the PESA (Progression of Early Subclinical Atherosclerosis) study, with no history of cardiovascular disease and with HbA1c in the nondiabetic range, were assessed for the presence and extent of SA by 2-dimensional vascular ultrasound and noncontrast cardiac computed tomography. Results: After adjusting for established CVRFs, HbA1c showed an association with the multiterritorial extent of SA (odds ratio: 1.05, 1.27, 1.27, 1.36, 1.80, 1.87, and 2.47 for HbA1c 4.9% to 5.0%, 5.1% to 5.2%, 5.3% to 5.4%, 5.5% to 5.6%, 5.7% to 5.8%, 5.9% to 6.0%, and 6.1% to 6.4%, respectively; reference HbA1c ≤4.8%; p < 0.001). The association was significant in all pre-diabetes groups and even below the pre-diabetes cut-off (HbA1c 5.5% to 5.6% odds ratio: 1.36 [95% confidence interval: 1.03 to 1.80]; p = 0.033). High HbA1c was associated with an increased risk of SA in low-risk individuals (p < 0.001), but not in moderate-risk individuals (p = 0.335). Relative risk estimations using Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease predictors confirmed that inclusion of HbA1c modified the risk of multiterritorial SA in most risk categories. Conclusions: Routine use of HbA1c can identify asymptomatic individuals at higher risk of SA on top of traditional CVRFs. Lifestyle interventions and novel antidiabetic medications might be considered to reduce both HbA1c levels and SA in individuals without diabetes.
Repisalud
Publication Artículo científico (JournalArticle)

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

  • Ghigo, Alessandra
  • Ameri, Pietro
  • Asnani, Aarti
  • Bertero, Edoardo
  • de Boer, Rudolf A
  • Farmakis, Dimitrios
  • González, Arantxa
  • Heymans, Stephane
  • Ibáñez, Borja
  • López-Fernández, Teresa
  • Lyon, Alexander R
  • Pollesello, Piero
  • Rakisheva, Amina
  • Stellos, Konstantinos
  • Streckfuss-Bömeke, Katrin
  • Tocchetti, Carlo Gabriele
  • Thum, Thomas
  • van der Meer, Peter
  • Van Rooij, Eva
  • Ponikowski, Piotr
  • Metra, Marco
  • Rosano, Giuseppe
  • Van Linthout, Sophie
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Repisalud
Publication Artículo científico (JournalArticle)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity.

Repisalud
Publication Artículo científico (JournalArticle)

The impact of type 2 immunity and allergic diseases in atherosclerosis.

  • Fernández-Gallego, Nieves
  • Castillo-González, Raquel
  • Méndez-Barbero, Nerea
  • López-Sanz, Celia
  • Obeso, David
  • Villaseñor, Alma
  • Escribese, María M
  • López-Melgar, Beatriz
  • Salamanca, Jorge
  • Benedicto-Buendía, Amparo
  • Jiménez-Borreguero, Luis Jesús
  • Ibáñez, Borja
  • Sastre, Joaquín
  • Belver, María Teresa
  • Vega, Francisco
  • Blanco, Carlos
  • Barber, Domingo
  • Sánchez-Madrid, Francisco
  • de la Fuente, Hortensia
  • Martin, Pilar
  • Esteban, Vanesa
  • Jiménez-Saiz, Rodrigo
  • Fernández‐Gallego, Nieves
  • Castillo‐González, Raquel
  • Méndez‐Barbero, Nerea
  • López‐Sanz, Celia
  • Escribese, María M.
  • López‐Melgar, Beatriz
  • Benedicto‐Buendía, Amparo
  • Jiménez‐Borreguero, Luis Jesús
  • Sánchez‐Madrid, Francisco
  • Jiménez‐Saiz, Rodrigo
Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).
Repisalud
Publication Artículo científico (JournalArticle)

Ischemic postconditioning fails to reduce infarct size in pig models of intermediate and prolonged ischemia

  • Nuche, Jorge
  • Galán-Arriola, Carlos
  • Fernández-Jiménez, Rodrigo
  • Higuero Verdejo, María Isabel
  • González Pastor, Victoria I.
  • Vazirani, Ravi
  • Lanaspa, Arturo
  • Anguita-Gámez, María
  • López Martín, Gonzalo J.
  • Sánchez González, Javier
  • Ibáñez, Borja
Repisalud
Publication Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis.

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors. However, individuals at risk for early vascular disease often remain unidentified. Recent research has identified new molecules in the pathophysiology of atherosclerosis, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP-I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP-I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis.
Repisalud
Publication Artículo científico (JournalArticle)

β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia-reperfusion injury.

  • Fernández-Tocino, Miguel
  • Pun-Garcia, Andrés
  • Gómez, Mónica
  • Clemente-Moragón, Agustín
  • Oliver, Eduardo
  • Villena-Gutierrez, Rocío
  • Trigo-Anca, Sofía
  • Díaz-Guerra, Anabel
  • Sanz-Rosa, David
  • Prados, Belén
  • Del Campo, Lara
  • Andrés, Vicente
  • Fuster, Valentín
  • de la Pompa, José Luis
  • Cádiz, Laura
  • Ibañez, Borja
β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia-reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this protection has remained unknown. Using transgenic mice constitutively expressing the human β3AR (hβ3AR) in cardiomyocytes or in the endothelium on a genetic background of null endogenous β3AR expression, we show that only cardiomyocyte expression protects against IRI (45 min ischemia followed by reperfusion over 24 h). Infarct size was also limited after ischemia-reperfusion in mice with cardiomyocyte hβ3AR overexpression on top of endogenous β3AR expression. hβ3AR overexpression in these mice reduced IRI-induced cardiac fibrosis and improved long-term left ventricular systolic function. Cardiomyocyte-specific β3AR overexpression resulted in a baseline remodeling of the mitochondrial network, characterized by upregulated mitochondrial biogenesis and a downregulation of mitochondrial quality control (mitophagy), resulting in elevated numbers of small mitochondria with a depressed capacity for the generation of reactive oxygen species but improved capacity for ATP generation. These processes precondition cardiomyocyte mitochondria to be more resistant to IRI. Upon reperfusion, hearts with hβ3AR overexpression display a restoration in the mitochondrial quality control and a rapid activation of antioxidant responses. Strong protection against IRI was also observed in mice infected with an adeno-associated virus (AAV) encoding hβ3AR under a cardiomyocyte-specific promoter. These results confirm the translational potential of increased cardiomyocyte β3AR expression, achieved either naturally through exercise or artificially through gene therapy approaches, to precondition the cardiomyocyte mitochondrial network to withstand future insults.
Repisalud
Publication Artículo científico (JournalArticle)

Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control

  • Díaz-Guerra, Anabel
  • Villena-Gutiérrez, Rocío
  • Clemente-Moragón, Agustín
  • Gómez, Mónica
  • Oliver, Eduardo
  • Fernández-Tocino, Miguel
  • Galán-Arriola, Carlos
  • Cádiz, Laura
  • Ibáñez, Borja
Repisalud
Publication Artículo científico (JournalArticle)

Bone marrow activation in response to metabolic syndrome and early atherosclerosis

  • Devesa, Ana
  • Lobo-González, Manuel
  • Martínez-Milla, Juan
  • Oliva, Belén
  • García-Lunar, Inés
  • Mastrangelo, Annalaura
  • España, Samuel
  • Sanz, Javier
  • Mendiguren, José M
  • Bueno, Hector
  • Fuster, Jose J.
  • Andres, Vicente
  • Fernández-Ortiz, Antonio
  • Sancho, David
  • Fernández-Friera, Leticia
  • Sanchez-Gonzalez, Javier
  • Rossello, Xavier
  • Ibáñez, Borja
  • Fuster, Valentin
Aims: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. Methods and results: Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). Conclusion: In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Optimizing high-quality graphene nanoflakes production through organic (bio)-precursor plasma decomposition

  • Casanova, Ana
  • Rincón, Rocío
  • Muñoz, José
  • Ania, Conchi O.
  • Calzada Canalejo, María Dolores
Atmospheric pressure plasma-based technique for the decomposition of biofuels allows obtaining high-quality graphene powder in one step, without the use of neither metal catalysts nor specific substrates. Despite the numerous advantages of this technology as compared to others, it is necessary to optimize the process to produce high-quality graphene at industrial scale. In this research, the influence of the ethanol flows in the 2.00 to 4.00 g h−1 range on the production rate and the quality of graphene has been thoroughly assessed, through a deep characterization of the synthetized material by various techniques. The graphene production rate steadily increased for ethanol flows increasing from 2.00 to 3.40 g h−1, presenting a maximum rate of 1.45 and 1.55 mg min−1 for 2.90 and 3.40 g h−1, respectively. Higher ethanol flows lead to a decrease in the production rate, favouring the formation of other carbon-based by-products such as methane and ethylene. High-quality graphene is formed in all plasma conditions, with the lowest number of defects being obtained for an ethanol flow of 2.90 g h−1 together with hydrogen and carbon monoxide as main gaseous by-products.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Crystalline water in gypsum is unavailable for cyanobacteria in laboratory experiments and in natural desert endolithic habitats

  • Wierzchos, Jacek
  • Artieda, Octavio
  • Ascaso, Carmen
  • Nieto García, Antonio
  • Vítek, Petr
  • Azua-Bustos, Armando
  • Fairén, Alberto G.
This work was supported by the following grants: PGC2018-094076-B-I00 MCIU/AEI (Spain) and FEDER (UE) to J.W., O.A., and C.A.; ERC-CoG 818602 to A.G.F. and A.A.-B.; LM2018123-CzeCOS (Czech Republic) to P.V.; and RGY0066/2018 to A.A.-B.
Archivo Digital UPM
Publication Contribución de congreso (ConferenceOutput)

Latent force models for earth observation time series prediction

Archivo Digital UPM
Publication Contribución de congreso (ConferenceOutput)

Physics-aware gaussian processes for earth observation

  • Camps-Valls, Gustau
  • Svendsen, Daniel H.
  • Martino, Luca
  • Muñoz Marí, Jordi
  • Laparra Pérez-Muelas, Valero
  • Campos-Taberner, Manuel
  • Luengo García, David|||0000-0001-7407-3630
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A saturated map of common genetic variants associated with human height

  • Yengo, Loic|||0000-0002-4272-9305
  • Vedantam, Sailaja|||0000-0003-3892-7461
  • Marouli, Eirini|||0000-0001-6179-1609
  • Sidorenko, Julia
  • Bartell, Eric
  • Sakaue, Saori|||0000-0003-3618-9717
  • Graff, Marielisa
  • Eliasen, Anders U.
  • Jiang, Yunxuan
  • Raghavan, Sridharan
  • Miao, Jenkai
  • Arias, Joshua D.
  • Graham, Sarah E.|||0000-0003-1271-2489
  • Mukamel, Ronen E.
  • Spracklen, Cassandra N.|||0000-0003-3590-7182
  • Yin, Xianyong|||0000-0001-6454-2384
  • Chen, Shyh-Huei
  • Ferreira, Teresa
  • Highland, Heather H.
  • Ji, Yingjie
  • Karaderi, Tugce|||0000-0001-9763-8139
  • Lin, Kuang
  • Lüll, Kreete
  • Malden, Deborah|||0000-0003-0567-8294
  • Medina-Gomez, Carolina|||0000-0001-7999-5538
  • Machado, Moara
  • Moore, Amy
  • Rüeger, Sina
  • Sim, Xueling|||0000-0002-1233-7642
  • Vrieze, Scott
  • Ahluwalia, Tarunveer Singh|||0000-0002-7464-3354
  • Akiyama, Masato|||0000-0002-1879-5476
  • Allison, Matthew A.
  • Álvarez, Marcus
  • Andersen, Mette korre|||0000-0001-8227-1469
  • Ani, Alireza|||0000-0002-7868-3118
  • Appadurai, Vivek
  • Arbeeva, Liubov|||0000-0001-5004-419X
  • Bhaskar, Seema
  • Bielak, Lawrence F.|||0000-0002-3443-8030
  • Bollepalli, Sailalitha|||0000-0002-8773-7149
  • Bonnycastle, Lori L.
  • Bork-Jensen, Jette
  • Bradfield, Jonathan Paul|||0000-0001-8758-2071
  • Bradford, Yuki
  • Braund, Peter S.|||0000-0001-8540-5709
  • Brody, Jennifer A.|||0000-0001-8509-148X
  • Burgdorf, Kristoffer S.
  • Cade, Brian E.|||0000-0003-1424-0673
  • Cai, H.
  • Cai, Qiuyin
  • Campbell, Archie|||0000-0003-0198-5078
  • Cañadas-Garre, Marisa|||0000-0003-1103-5658
  • Catamo, Eulalia|||0000-0002-4701-9134
  • Chai, Jin-Fang|||0000-0003-3770-1137
  • Chai, Xiaoran
  • Chang, Liching
  • Chang, Yicheng
  • Chen, Chien Hsiun
  • Chesi, Alessandra|||0000-0002-0954-7446
  • Choi, Seunghoan
  • Chung, Renhua
  • Cocca, Massimiliano|||0000-0002-1127-7596
  • Concas, Maria Pina|||0000-0003-3598-2537
  • Couture, Christian Y.
  • Cuellar-Partida, Gabriel|||0000-0001-7648-4097
  • Danning, Rebecca D.
  • Daw, E. Warwick
  • Degenhard, Frauke
  • Delgado, Graciela E.|||0000-0002-1272-7210
  • Delitala, Alessandro|||0000-0003-1729-8969
  • Demirkan, Ayşe|||0000-0002-7546-0867
  • Deng, Xuan|||0000-0003-0918-817X
  • Devineni, Poornima
  • Dietl, Alexander|||0000-0002-4091-8620
  • Dimitriou, Maria E.
  • Dimitrov, Latchezar M.
  • Dorajoo, Rajkumar|||0000-0001-6608-2051
  • Ekici, Arif B.
  • Engmann, Jorgen|||0000-0001-7015-7773
  • Fairhurst-Hunter, Zammy
  • Farmaki, Aliki Eleni
  • Faul, Jessica D.|||0000-0002-6969-6478
  • Fernandez-Lopez, Juan Carlos|||0000-0003-3680-4193
  • Forer, Lukas|||0000-0003-2139-7329
  • Francescatto, Margherita
  • Freitag-Wolf, Sandra
  • Fuchsberger, Christian|||0000-0002-5918-8947
  • Galesloot, Tessel E.
  • Gao, Yan
  • Gao, Zishan|||0000-0003-1299-0286
  • Geller, Frank
  • Giannakopoulou, Olga
  • Giulianini, Franco
  • Gjesing, Anette Prior
  • Goel, Anuj|||0000-0003-2307-4021
  • Gordon, Scott D.|||0000-0001-7623-328X
  • Gorski, Mathias M.
  • Grove, Jakob|||0000-0003-2284-5744
  • Guo, Xiuqing
  • Gustafsson, S.|||0000-0001-5894-0351
  • Haessler, Jeffrey W.
  • Hansen, Thomas Folkmann
  • Havulinna, Aki Samuli
  • Haworth, S.J.
  • He, Jing
  • Heard-Costa, Nancy L.
  • Hebbar, Prashantha|||0000-0001-6560-7063
  • Hindy, George|||0000-0002-7257-9299
  • Ho, Yuk Lam Anne
  • Hofer, Edith
  • Holliday, Elizabeth|||0000-0002-4066-6224
  • Horn, Katrin
  • Hornsby, Whitney E.
  • Hottenga, Jouke Jan|||0000-0002-5668-2368
  • Huang, Hongyan
  • Huang, Jie
  • Huerta-Chagoya, Alicia|||0000-0001-6218-3904
  • Huffman, Jennifer E.|||0000-0002-9672-2491
  • Hung, Yijen
  • Huo, Shaofeng
  • Hwang, Mi-yeong
  • Iha, Hiroyuki|||0000-0003-4261-2067
  • Ikeda, Daisuke D.|||0000-0001-8403-0327
  • Isono, Masato
  • Jackson, Anne U.|||0000-0002-9672-2547
  • Jäger, Susanne
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Johansson, Ingegerd
  • Jonas, Jost Bruno
  • Jonsson, Anna Elisabet
  • Jørgensen, Torben J.
  • Kalafati, IP.|||0000-0001-5572-7491
  • Kanai, Masahiro|||0000-0001-5165-4408
  • Kanoni, Stavroula|||0000-0002-1691-9615
  • Kårhus, Line Lund
  • Kasturiratne, Anuradhani
  • Katsuya, Tomohiro|||0000-0002-8892-8828
  • Kawaguchi, Takahisa
  • Kember, Rachel L.|||0000-0001-8820-2659
  • Kentistou, Katherine A.|||0000-0002-5816-664X
  • Kim, Hanna
  • Kim, Young-jin
  • Kleber, Marcus Edi
  • Knol, Maria J.|||0000-0002-3597-1531
  • Kurbasic, Azra
  • Lauzon, Marie
  • Le, Phuong
  • Lea, Rodney A.
  • Lee, Jongyoung
  • Leonard, Hampton L.|||0000-0003-2390-8110
  • Li, Shengchao Alfred
  • Li, Xiaoyin
  • Liang, Jingjing
  • Lin, Honghuang
  • Lin, Shihyi
  • Liu, Jun|||0000-0001-5288-3042
  • Liu, Xueping
  • Lo, Ken Sin
  • Long, Jirong
  • Lores-Motta, Laura
  • Luan, Jian'fan N. An
  • Lyssenko, Valeriya
  • Lyytikäinen, Leo Pekka
  • Mahajan, Anubha|||0000-0001-5585-3420
  • Mamakou, Vasiliki
  • Mangino, Massimo
  • Manichaikul, Ani W.
  • Marten, Jonathan|||0000-0001-6916-2014
  • Mattheisen, Manuel|||0000-0002-8442-493X
  • Mavarani, Laven
  • McDaid, Aaron F.
  • Meidtner, Karina
  • Melendez, Tori L.
  • Mercader, Josep M.|||0000-0001-8494-3660
  • Milaneschi, Yuri|||0000-0002-3697-6617
  • Miller, Jason E.
  • Millwood, Iona Y.
  • Mishra, Pashupati P.|||0000-0001-5177-3431
  • Mitchell, Ruth E.
  • Møllehave, Line Tang|||0000-0001-7116-9346
  • Morgan, Anna
  • Mucha, Soeren
  • Munz, Matthias|||0000-0002-4728-3357
  • Nakatochi, Masahiro|||0000-0002-1838-4837
  • Nelson, Christopher P.
  • Nethander, Maria
  • Nho, Chu Won
  • Nielsen, Aneta A.
  • Nolte, Ilja M.|||0000-0001-5047-4077
  • Nongmaithem, Suraj S.|||0000-0001-5390-0449
  • Noordam, Raymond|||0000-0001-7801-809X
  • Ntalla, Ioanna
  • Nutile, Teresa
  • Pandit, Anita
  • Christofidou, Paraskevi
  • Pärna, Katri
  • Pauper, Marc
  • Petersen, Eva R.B.
  • Petersen, Liselotte V.
  • Pitkänen, Niina
  • Polašek, Ozren
  • Poveda, Alaitz|||0000-0001-6349-3955
  • Preuss, Michael H.
  • Pyarajan, Saiju
  • Raffield, Laura M.
  • Rakugi, Hiromi
  • Ramirez, Julia
  • Rasheed, Asif
  • Raven, Dennis
  • Rayner, Nigel W.
  • Riveros, Carlos
  • Rohde, Rebecca
  • Ruggiero, Daniela|||0000-0003-3898-7827
  • Ruotsalainen, Sanni E.|||0000-0002-1631-4069
  • Ryan, Kathleen A.
  • Sabater-Lleal, Maria|||0000-0002-0128-379X
  • Saxena, Richa
  • Scholz, Markus|||0000-0002-4059-1779
  • Sendamarai, Anoop
  • Shen, Botong
  • Shi, Jingchunzi
  • Shin, J.H.
  • Sidore, Carlo|||0000-0001-7504-7477
  • Sitlani, Collen M.|||0000-0001-7656-7482
  • Slieker, Roderick C.
  • Smit, Roelof A. J.
  • Smith, Albert V.
  • Smith, Jennifer A.|||0000-0002-3575-5468
  • Smyth, Laura J.|||0000-0001-6419-4826
  • Southam, Lorraine
  • Steinthorsdottir, Valgerdur
  • Sun, Liang
  • Takeuchi, Fumihiko
  • Tallapragada, Divya Sri Priyanka
  • Taylor, Kent|||0000-0002-2756-4370
  • Tayo, Bamidele O.
  • Tcheandjieu, Catherine
  • Terzikhan, Natalie
  • Tesolin, Paola|||0000-0002-5238-6422
  • Teumer, Alexander|||0000-0002-8309-094X
  • Theusch, Elizabeth|||0000-0002-5678-759X
  • Thompson, Deborah J.
  • Thorleifsson, Gudmar|||0000-0003-4623-9087
  • Timmers, Paul R. H. J.
  • Trompet, Stella|||0000-0001-5006-0528
  • Turman, Constance
  • Vaccargiu, Simona
  • van der Laan, Sander W.|||0000-0001-6888-1404
  • van der Most, Peter J.|||0000-0001-8450-3518
  • van Klinken, Jan Bert
  • van Setten, Jessica A.
  • Verma, Shefali Setia
  • Verweij, Niek|||0000-0002-4303-7685
  • Veturi, Yogasudha C.
  • Wang, Carol A.|||0000-0002-4301-3974
  • Wang, Chaolong
  • Wang, Lihua
  • Wang, Zhe|||0000-0003-0786-9887
  • Warren, Helen R.
  • Bin Wei, Wen
  • Wickremasinghe, Ananda|||0000-0002-6174-6784
  • Wielscher, Matthias|||0000-0003-4138-1383
  • Wiggins, Kerri L.|||0000-0003-2749-1279
  • Winsvold, Bendik Slagsvold|||0000-0003-4171-8919
  • Wong, Andrew|||0000-0003-2079-4779
  • Wu, Yang|||0000-0002-0128-7280
  • Wuttke, Matthias|||0000-0003-3420-5082
  • Xia, Rui|||0000-0003-2409-1181
  • Xie, Tian
  • Yamamoto, Ken
  • Yang, Jingyun
  • Yao, Jie
  • Young, Hannah|||0000-0002-4248-9612
  • Yousri, Noha A.|||0000-0003-1918-0331
  • Yu, Lei
  • Zeng, Lingyao
  • Zhang, Weihua
  • Zhang, Xinyuan
  • Zhao, Jinghua
  • Zhao, Wei|||0000-0002-4839-6791
  • Zhou, Wei
  • Zimmermann, Martina E.|||0000-0002-6916-4404
  • Zoledziewska, Magdalena|||0000-0002-3033-6133
  • Adair, Linda S.
  • Adams, Hieab H. H.|||0000-0003-3687-2508
  • Aguilar-Salinas, Carlos Alberto
  • Al-Mulla, Fahd|||0000-0001-5409-3829
  • Arnett, Donna|||0000-0003-2219-657X
  • Asselbergs, Folkert W.|||0000-0002-1692-8669
  • Åsvold, Bjørn Olav|||0000-0003-3837-2101
  • Attia, John Richard
  • Banas, Bernhard|||0000-0003-2076-2195
  • Bandinelli, Stefania|||0000-0002-6491-0850
  • Bennett, David Alan
  • Bergler, Tobias
  • Bharadwaj, Dwaipayan
  • Biino, Ginevra|||0000-0002-9936-946X
  • Bisgaard, Hans
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Böger, Carsten A.
  • Bønnelykke, Klaus
  • Boomsma, Dorret I.|||0000-0002-7099-7972
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Borja, Judith B.
  • Bouchard, Claude|||0000-0002-0048-491X
  • Bowden, Donald W.
  • Brandslund, Ivan
  • Brumpton, Ben
  • Buring, Julie E.
  • Caulfield, Mark|||0000-0001-9295-3594
  • Chambers, John C.
  • Chandak, Giriraj R.
  • Chanock, Stephen|||0000-0002-2324-3393
  • Chaturvedi, Nish
  • Chen, Yii Der Ida
  • Chen, Zhengming|||0000-0001-6423-105X
  • Cheng, Ching-Yu|||0000-0003-0655-885X
  • Christophersen, Ingrid E.
  • Ciullo, Marina|||0000-0002-9621-9984
  • Cole, John W.|||0000-0001-9263-8930
  • Collins, Francis S.|||0000-0002-1023-7410
  • Cooper, Richard S.
  • Cruz, Miguel
  • Cucca, Francesco|||0000-0002-7414-1995
  • Cupples, L. Adrienne
  • Cutler, Michael J.
  • Damrauer, Scott M.|||0000-0001-8009-1632
  • Dantoft, Thomas M.
  • de Borst, Gert J.
  • de Groot, Lisette C.P.G.M.|||0000-0003-2778-2789
  • De Jager, Philip L.|||0000-0002-8057-2505
  • de Kleijn, D.P.V.|||0000-0003-2714-2140
  • Janaka de Silva, H.
  • Dedoussis, George V.
  • den Hollander, Anneke I.
  • Du, Shufa
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Elders, Petra J. M.
  • Eliassen, A. Heather Heather
  • Ellinor, Patrick T.
  • Elmståhl, Sölve
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Evans, Michele K.
  • Fatkin, Diane
  • Feenstra, Bjarke|||0000-0003-1478-649X
  • Feitosa, Mary|||0000-0002-0933-2410
  • Ferrucci, Luigi
  • Ford, Ian
  • Fornage, Myriam|||0000-0003-0677-8158
  • Franke, Andre|||0000-0003-1530-5811
  • Franks, Paul W.|||0000-0002-0520-7604
  • Freedman, Barry I.|||0000-0003-0275-5530
  • Gasparini, Paolo
  • Gieger, Christian|||0000-0001-6986-9554
  • Girotto, Giorgia|||0000-0003-4507-6589
  • Goddard, Michael E.
  • Golightly, Yvonne M.
  • Gonzalez-Villalpando, Clicerio
  • Gordon-Larsen, P.
  • Grallert, H.
  • Grant, Struan F. A.|||0000-0003-2025-5302
  • Grarup, Niels|||0000-0001-5526-1070
  • Griffiths, L.
  • Gudnason, V.
  • Haiman, C.
  • Hakonarson, Hakon|||0000-0003-2814-7461
  • Hansen, Torben|||0000-0001-8748-3831
  • Hartman, C.A.
  • Hattersley, A.T.
  • Hayward, Caroline|||0000-0002-9405-9550
  • Heckbert, S.R.
  • Heng, C.K.
  • Hengstenberg, C.
  • Hewitt, Alex W.|||0000-0002-5123-5999
  • Hishigaki, H.
  • Hoyng, C.B.
  • Huang, Paul L.
  • Huang, W.
  • Hunt, S.C.
  • Hveem, K.
  • Hyppönen, E.
  • Iacono, William
  • Ichihara, S.
  • Ikram, M.A.
  • Isasi, C.R.
  • Jackson, R.D.
  • Jarvelin, Marjo-Riitta|||0000-0002-2149-0630
  • Jin, Zi-Bing
  • Jöckel, K.H.
  • Joshi, P.K.
  • Jousilahti, P.
  • Jukema, J.W.
  • Kähönen, M.
  • Kamatani, Yoichiro|||0000-0001-8748-5597
  • Kang, K.D.
  • Kaprio, Jaakko|||0000-0002-3716-2455
  • Kardia, S.L.R.
  • Karpe, F.
  • Kato, N.
  • Kee, F.
  • Kessler, T.
  • Khera, Amit V.
  • Khor, C.C.
  • Kiemeney, Lambertus A.
  • Kim, B.J.
  • Kim, E.K.
  • Kim, H.L.
  • Kirchhof, P.
  • Kivimaki, Mika|||0000-0002-4699-5627
  • Koh, W.P.
  • Koistinen, H.A.
  • Kolovou, G.D.
  • Kooner, J.S.
  • Kooperberg, C.
  • Köttgen, A.
  • Kovacs, P.
  • Kraaijeveld, A.
  • Kraft, Peter
  • Krauss, R.M.
  • Kumari, M.
  • Kutalik, Zoltan|||0000-0001-8285-7523
  • Laakso, Markku|||0000-0002-3394-7749
  • Lange, Leslie A.
  • Langenberg, C.
  • Launer, L.J.
  • Le Marchand, L.
  • Lee, H.
  • Lee, N.R.
  • Lehtimäki, T.
  • Li, H.
  • Li, L.
  • Lieb, Wolfgang|||0000-0003-2544-4460
  • Lin, X.
  • Lind, Lars
  • Linneberg, Allan|||0000-0002-0994-0184
  • Liu, Ching-Ti
  • Liu, Jianjun|||0000-0002-3255-3019
  • Loeffler, Markus
  • London, Barry
  • Lubitz, Steven A.
  • Lye, Stephen J.
  • Mackey, David A.
  • Mägi, Reedik
  • Magnusson, Patrik K. E.|||0000-0002-7315-7899
  • Marcus, Gregory M.|||0000-0001-5197-7696
  • Vidal, Pedro M.
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • März, Winfried|||0000-0001-6083-8946
  • Matsuda, Fumihiko
  • McGarrah, Robert W.
  • McGue, Matt|||0000-0002-5580-1433
  • McKnight, Amy Jayne|||0000-0002-7482-709X
  • Medland, Sarah Elizabeth|||0000-0003-1382-380X
  • Mellström, Dan|||0000-0003-2761-3723
  • Metspalu, Andres|||0000-0002-3718-796X
  • Mitchell, Braxton|||0000-0003-4920-4744
  • Mitchell, Paul
  • Mook-Kanamori, Dennis O.
  • Morris, Andrew D.
  • Mucci, Lorelei A.
  • Munroe, Patricia B.|||0000-0002-4176-2947
  • Nalls, Mike A.
  • Nazarian, Saman
  • Nelson, Amanda E.
  • Neville, Matt J.|||0000-0002-6004-5433
  • Newton-Cheh, Christopher
  • Nielsen, Christopher S.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Ohlsson, Claes|||0000-0002-9633-2805
  • Oldehinkel, Albertine J.|||0000-0003-3925-3913
  • Orozco, Lorena|||0000-0002-5801-9180
  • Pahkala, Katja
  • Pajukanta, Päivi
  • Palmer, Colin N. A.
  • Parra, Esteban J.|||0000-0002-2057-8577
  • Pattaro, Cristian|||0000-0002-4119-0109
  • Pedersen, Oluf
  • Pennell, Craig E.|||0000-0002-0937-6165
  • Penninx, Brenda W. J. H.
  • Pérusse, Louis|||0000-0001-6440-9698
  • Peters, Annette|||0000-0001-6645-0985
  • Peyser, Patricia A.
  • Porteous, David J.|||0000-0003-1249-6106
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Power, Chris
  • Pramstaller, Peter P.
  • Province, Michael A.|||0000-0001-6102-774X
  • Qi, Qibin
  • Qu, Jia
  • Rader, Daniel J.
  • Raitakari, Olli T.
  • Ralhan, Sarju
  • Rallidis, Loukianos S.
  • Rao, Dabeeru C.
  • Redline, Susan
  • Reilly, Dermot F.
  • Reiner, Alexander P.
  • Rhee, Sang Youl|||0000-0003-0119-5818
  • Ridker, Paul M.
  • Rienstra, Michiel|||0000-0002-2581-070X
  • Ripatti, Samuli|||0000-0002-0504-1202
  • Ritchie, Marylyn D.|||0000-0002-1208-1720
  • Roden, Dan M.
  • Rosendaal, Frits|||0000-0003-2558-7496
  • Rotter, Jerome I.|||0000-0001-7191-1723
  • Rudan, Igor|||0000-0001-6993-6884
  • Rutters, Femke
  • Sabanayagam, Charumathi|||0000-0002-4042-4719
  • Saleheen, Danish|||0000-0001-6193-020X
  • Salomaa, Veikko|||0000-0001-7563-5324
  • Samani, Nilesh J.
  • Sanghera, Dharambir K.
  • Sattar, Naveed|||0000-0002-1604-2593
  • Schmidt, Börge
  • Schmidt, Helena|||0000-0001-9773-9992
  • Schmidt, Reinhold
  • Schulze, Matthias B.
  • Schunkert, Heribert|||0000-0001-6428-3001
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Sever, Peter
  • Shiroma, Eric J.
  • Shoemaker, M. Benjamin
  • Shu, Xiao-Ou
  • Simonsick, Eleanor M.
  • Sims, Mario
  • Singh, Jai Rup
  • Singleton, Andrew B.|||0000-0001-5606-700X
  • Sinner, Moritz F.
  • Smith, J. Gustav
  • Snieder, Harold|||0000-0003-1949-2298
  • Spector, Tim|||0000-0002-9795-0365
  • Stampfer, Meir J.
  • Stark, Klaus J.
  • Strachan, David P.
  • 't Hart, Leen M.
  • Tabara, Yasuharu
  • Tang, Hua
  • Tardif, J.C.
  • Thanaraj, T.A.
  • Timpson, N.J.
  • Tönjes, A.
  • Tremblay, A.
  • Tuomi, T.
  • Tuomilehto, J.
  • Tusié-Luna, M.T.
  • Uitterlinden, André G.|||0000-0002-7276-3387
  • van Dam, Rob M.
  • van der Harst, Pim|||0000-0002-2713-686X
  • Van der Velde, Nathalie
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • van Schoor, N.M.
  • Vitart, Veronique|||0000-0002-4991-3797
  • Völker, U.
  • Vollenweider, P.
  • Völzke, Henry|||0000-0001-7003-399X
  • Wacher-Rodarte, N.H.
  • Walker, M.
  • Wang, Y.X.
  • Wareham, N.J.
  • Watanabe, R.M.
  • Watkins, Hugh
  • Weir, D.R.
  • Werge, Thomas M.
  • Widen, E.
  • Wilkens, Lynne R.
  • Willemsen, Gonneke|||0000-0003-3755-0236
  • Willett, Walter C.
  • Wilson, James F.|||0000-0001-5751-9178
  • Wong, Tien-Yin
  • Woo, Jeong-Taek|||0000-0001-9201-0713
  • Wright, Alan F.
  • Wu, Jer-Yuarn
  • Xu, Huichun|||0000-0001-8118-9607
  • Yajnik, Chittaranjan S.
  • Yokota, Mitsuhiro
  • Yuan, Jian-Min|||0000-0002-4620-3108
  • Zeggini, Eleftheria|||0000-0003-4238-659X
  • Zemel, Babette S.
  • Zheng, Wei|||0000-0003-1226-070X
  • Zhu, X.|||0000-0003-0037-411X
  • Zmuda, Joseph M.
  • Zonderman, Alan B.|||0000-0002-6523-4778
  • Zwart, John-Anker|||0000-0001-5721-0154
  • Croteau-Chonka, Damien
  • Vonk, Judith M.
  • Le Marchand, Loic
  • Chasman, Daniel I.|||0000-0003-3357-0862
  • Cho, Yoon Shin
  • Heid, Iris M.
  • McCarthy, Mark I.
  • Ng, Maggie C. Y.
  • O'Donnell, Christopher J.
  • Rivadeneira, Fernando|||0000-0001-9435-9441
  • Thorsteinsdottir, Unnur
  • Sun, Yan V.|||0000-0002-2838-1824
  • Tai, E. Shyong
  • Boehnke, Michael|||0000-0002-6442-7754
  • Deloukas, Panos|||0000-0001-9251-070X
  • Justice, Anne E.
  • Lindgren, Cecilia M.
  • Loos, Ruth J. F.|||0000-0002-8532-5087
  • Mohlke, Karen L.|||0000-0001-6721-153X
  • North, Kari E.
  • Stefánsson, Kári|||0000-0003-1676-864X
  • Walters, Robin G.|||0000-0002-9179-0321
  • Winkler, Thomas W.|||0000-0003-0292-5421
  • Young, Kristin L.|||0000-0003-0070-6145
  • Loh, Po-Ru
  • Yang, Jian|||0000-0003-4800-832X
  • Esko, Tõnu
  • Assimes, Themistocles|||0000-0003-2349-0009
  • Auton, Adam
  • Abecasis, Goncalo
  • Willer, Cristen J.|||0000-0001-5645-4966
  • Locke, Adam E.|||0000-0001-6227-198X
  • Berndt, Sonja
  • Lettre, Guillaume
  • Frayling, Timothy M.
  • Okada, Yukinori|||0000-0002-0311-8472
  • Wood, Andrew R.|||0000-0003-1726-948X
  • Visscher, PM.|||0000-0002-2143-8760
  • Hirschhorn, Joel N.|||0000-0002-1650-7901
Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40-50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes. Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel) account for 40% (45%) of phenotypic variance in populations of European ancestry but only around 10-20% (14-24%) in populations of other ancestries. Effect sizes, associated regions and gene prioritization are similar across ancestries, indicating that reduced prediction accuracy is likely to be explained by linkage disequilibrium and differences in allele frequency within associated regions. Finally, we show that the relevant biological pathways are detectable with smaller sample sizes than are needed to implicate causal genes and variants. Overall, this study provides a comprehensive map of specific genomic regions that contain the vast majority of common height-associated variants. Although this map is saturated for populations of European ancestry, further research is needed to achieve equivalent saturation in other ancestries.